本站原创[摘 要 ] 目的 评价金水宝片佐助厄贝沙坦片治疗慢性肾小球肾炎（CGN）患者的疗效. 方法 100例CGN患者随机分成观察组和对照组.对照组给予厄贝沙坦片治疗；观察组采用金水宝片佐助厄贝沙坦片治疗. 结果 观察组完全缓解率及总缓解率均高于对照组（P＜0.05）；观察组24 h尿蛋白定量及Scr改善情况均优于对照组（P＜0.01）；两组均未见明显不良反应. 结论 金水宝片佐助厄贝沙坦片治疗CGN患者疗效佳,具有重要的临床价值.
[关 键 词 ] 慢性肾小球肾炎；金水宝片；厄贝沙坦片
[中图分类号] R256.5；R692.3+1 [文献标识码] B [文章编号] 1673-9701（2012）01-073-02
Clinical research of cordyceps militaris tablets and irbesartan tablets in treatment of chronic glomerulonephritis
YANG Yong SONG Xuequan WANG Xiaoyi SHI Zhanqin DING Min
Department of Nephrology, the First People's Hospital of Huzhou City in Zhejiang Province, Huzhou 313000, China
[Abstract] Objective To evaluate the efficacy of cordyceps militaris tablets and irbesartan tablets in treatment of chronic glomerulonephritis(CGN). Methods One hundred cases of CGN patients were randomly divided into the observation group and the control group. The control group was treated with irbesartan tablets, and the observation group was treated with cordyceps militaris tablets and irbesartan tablets. Results Complete remission rate and overall response rate of the observation group were higher than those of the control group(P＜0.05), 24 h urinary protein and Scr improvements of the observation group were better than those of the control group (P＜0.01). Both groups had no obvious adverse reactions. Conclusion Cordyceps militaris tablets and irbesartan tablets in treatment of chronic glomerulonephritis has good efficacy and important clinical value.
[Key words] Chronic glomerulonephritis, Cordyceps militaris tablets, Irbesartan tablets
慢性肾小球肾炎（chronic glomerulonephritis,CGN）简称慢性肾炎,以水肿、血尿、蛋白尿、高血压、肾功能减退等为主要特征,如不及时治疗,最终可发展至慢性肾功能衰竭[1].本课题中,笔者采用金水宝片佐助厄贝沙坦片治疗了CGN患者,取得较佳疗效,现报道如下.
1.资料与方法
1.1 病例选择标准
纳入标准：符合2003年海口市会议所制订的慢性肾炎诊断标准；24 h尿蛋白定量＜3.5 g/24 h；血肌酐（Scr）＜350 μmol/L；血尿素氮（BUN）＜17 mmol/L；患者及家属同意并签订知情同意书.排除标准：糖尿病、继发性肾小球疾病及伴有严重危及生命疾病的患者.
1.2 一般资料
选择2010年1月～2011年9月在本院就诊的CGN患者100例,男59例,女41例,年龄22～57岁,病程6个月～5年.患者按就诊顺序随机分成观察组和对照组两组：观察组50例,男30例,女20例,平均年龄（37.4±5.6）岁,病程（2.4±0.9）年；对照组50例,男29例,女21例,平均年龄（36.8±7.2）岁,病程（2.6±0.8）年.两组患者的性别、年龄、病程等一般资料差异无统计学意义（P＞0.05）,具有可比性.
1.3 治疗方法
对照组：厄贝沙坦片（修正药业,国药准字H20053912）,口服,0.3 g/d；辅以抗凝、利尿等其他对症、支持治疗.观察组：在对照组治疗方式的基础上,加用金水宝片（江西金水宝制药,国药准字Z10910014）,口服,一次5片,3次/d.两组均治疗8周后评价疗效,并评价24 h尿蛋白定量、血尿素氮（BUN）、血肌酐（Scr）等临床指标.
1.4 疗效评价